Search - tctmd.com

Displaying 1 - 20 of 50

Sort: Relevancy | Date

News Daily News

Top Heart Failure News of 2024

Todd Neale

December 31, 2024

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

News Daily News

PREVENT Tool Accurately Predicts HF Risk, With ‘Strong’ ASCVD Overlap

Yael L. Maxwell

December 17, 2024

News Daily News

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

L.A. McKeown

December 13, 2024

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

L.A. McKeown

October 11, 2024

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

News Daily News

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

Todd Neale

September 26, 2024

News Daily News

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

Michael O'Riordan

September 24, 2024

News Conference News ESC 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

Shelley Wood

September 01, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Presentation ESC 2024

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Presenter: Muthiah Vaduganathan

September 01, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Yael L. Maxwell

August 01, 2024

Advertisement

Top Heart Failure News of 2024

December 2024 Dispatch for the CV Team

PREVENT Tool Accurately Predicts HF Risk, With ‘Strong’ ASCVD Overlap

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

November 2024 Dispatch for the CV Team

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

AHA Statement Outlines Cardiac Contributions to Brain Health

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content